GlucoTrack, Inc.

NasdaqCM:GCTK Stock Report

Market Cap: US$1.9m

GlucoTrack Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Paul Goode

Chief executive officer

US$483.2k

Total compensation

CEO salary percentage46.6%
CEO tenureless than a year
CEO ownership1.7%
Management average tenure2.3yrs
Board average tenure4.5yrs

Recent management updates

Recent updates

GlucoTrack to start R&D program for glucose monitoring system

Oct 10

CEO Compensation Analysis

How has Paul Goode's remuneration changed compared to GlucoTrack's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$15m

Jun 30 2024n/an/a

-US$12m

Mar 31 2024n/an/a

-US$10m

Dec 31 2023US$483kUS$225k

-US$8m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023n/an/a

-US$6m

Mar 31 2023n/an/a

-US$5m

Dec 31 2022US$540kUS$201k

-US$4m

Sep 30 2022n/an/a

-US$5m

Jun 30 2022n/an/a

-US$5m

Mar 31 2022n/an/a

-US$4m

Dec 31 2021US$29kn/a

-US$4m

Sep 30 2021n/an/a

-US$3m

Jun 30 2021n/an/a

-US$3m

Mar 31 2021n/an/a

-US$3m

Dec 31 2020US$1kn/a

-US$3m

Compensation vs Market: Paul's total compensation ($USD483.24K) is about average for companies of similar size in the US market ($USD649.07K).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.

CEO

Paul Goode (56 yo)

less than a year

Tenure

US$483,243

Compensation

Mr. Paul V. Goode, Ph D., serves as Chief Executive Officer and President at GlucoTrack, Inc and also serves as its Director since September 2024. He served as President and Chief Operating Officer at Gluc...

Leadership Team

NamePositionTenureCompensationOwnership
Paul Goode
CEO, President & Directorno dataUS$483.24k1.71%
$ 32.2k
Mark Tapsak
Vice President of Technology2.3yrsUS$176.21k0.023%
$ 433.7
Drinda Benjamin
Vice President of Marketing1.5yrsno data0.0049%
$ 92.8
James Thrower
Vice President of Engineeringno dataUS$264.11k0.0099%
$ 185.7
Avner Gal
Co-Founder24yrsUS$187.39kno data
David Malka
Co-Founder24yrsUS$199.35kno data
James Cardwell
Chief Financial Officer1.3yrsno datano data
Vincent Wong
VP of Qualityno datano data0.0099%
$ 185.7

2.3yrs

Average Tenure

56yo

Average Age

Experienced Management: GCTK's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul Goode
CEO, President & Directorless than a yearUS$483.24k1.71%
$ 32.2k
Avner Gal
Co-Founder7.8yrsUS$187.39kno data
Luis Malave
Independent Chairman3.6yrsUS$70.00k0.14%
$ 2.6k
Irl Hirsch
Member of Scientific & Clinical Advisory Boardno datano datano data
Robert Fischell
Independent Director15yrsUS$70.00k0.072%
$ 1.4k
Lutz Heinemann
Member of Scientific & Clinical Advisory Board9.9yrsno datano data
Barry Ginsberg
Member of Scientific & Clinical Advisory Boardno datano datano data
Allen Danzig
Independent Director5.3yrsUS$70.00k0.053%
$ 990.9
David Klonoff
Chair of Scientific Advisory Board3.8yrsno datano data
Erin Carter
Independent Director1.4yrsUS$23.33k0.17%
$ 3.2k
Michael Heise
Member of Scientific & Clinical Advisory Boardno datano datano data
Jan Bolinder
Member of Scientific & Clinical Advisory Boardno datano datano data

4.5yrs

Average Tenure

67yo

Average Age

Experienced Board: GCTK's board of directors are considered experienced (4.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/13 08:43
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GlucoTrack, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution